Berberine‐Pretreated Bone Marrow Mesenchymal Stem Cells Accelerate Skin Wound Healing in Rats With Burn Injuries Authors: Jinglei Tan, Caiqiang Chen Published: 2026 ABSTRACT ABSTRACTBerberine (BBR) is a natural isoquinoline alkaloid with antibacterial, anti‐inflammatory and pro‐angiogenic properties. This study aimed to investigate the therapeutic efficacy and underlying mechanism of a conditioned medium (CM) derived from berberine‐preconditioned bone marrow‐derived mesenchymal stem cells (BMSCs‐BBR). BMSCs were isolated and phenotypically characterised by flow cytometry. A burn wound model was established in Wistar rats, and the model rats were randomly allocated to four groups treated with placebo gel, standard BMSCs‐CM gel, BMSCs‐BBR CM gel, or silver sulfadiazine cream. Wound healing rates were monitored macroscopically. On Day 21, skin tissues were harvested for histological analysis (H&E and Masson's trichrome staining), followed by immunofluorescence staining (CD31) and Western blot analysis (Collagen I, Collagen III and key proteins in the PI3K/AKT/eNOS signalling pathway). Among all treatments, BMSCs‐BBR CM accelerated wound closure the most significantly, accompanied by improved epidermal regeneration, enhanced collagen deposition and organisation and a marked increase in capillary density. Furthermore, wounds treated with BMSCs‐BBR CM exhibited notably upregulated Collagen I and Collagen III, and activation of the PI3K/AKT/eNOS pathway, as evidenced by increased phosphorylation of PI3K and AKT and elevated eNOS protein levels. Our findings demonstrate that the topical application of BMSCs‐BBR CM gel potently promotes burn wound healing by improving the quality of tissue regeneration and stimulating angiogenesis via the activation of the PI3K/AKT/eNOS signalling pathway. This preconditioning strategy represents a promising acellular therapeutic approach for burn wound management. Introduction Burn injuries rank as the fourth most common type of trauma globally, following road traffic accidents, falls and interpersonal violence and lead to approximately 6 million hospital admissions annually [1, 2]. Such injuries are characterised by substantial non‐viable tissue, excessive exudate production, a high susceptibility to infection and a pronounced tendency for scar formation [3, 4]. Severe burns initiate a systemic inflammatory response syndrome, which critically increases capillary permeability and vascular resistance, culminating in significantly elevated patient mortality and morbidity [5]. While early surgical debridement and autografting remain the standard of care for deep burns, a major clinical challenge persists for patients with extensive injuries due to the limited availability of autologous skin [6]. In response, recent innovations in regenerative medicine, particularly stem cell‐based biomaterials and advanced skin substitutes, present promising strategies for enhancing wound repair and tissue regeneration. Bone marrow mesenchymal stromal cells (BMSCs) possess self‐renewal ability and multilineage differentiation potential [7]. Their therapeutic benefits are largely attributed to paracrine factors that promote antiapoptotic, angiogenic and mitogenic activities [8, 9]. BMSCs facilitate wound repair through multiple pathways, including re‐epithelialisation via keratinocyte differentiation, dermal reconstruction through fibroblast differentiation and enhanced vascularisation by endothelial cell commitment [10]. Additionally, the secretion of cytokine and chemokine by BMSCs plays a critical role in regulating processes such as angiogenesis during inflammatory and proliferative phases of wound healing [11]. Nevertheless, emerging evidence has indicated that phytochemicals can activate specific signalling pathways to enhance mesenchymal stromal cell (MSC) migration, thereby mobilising these cells towards damaged tissues and promoting regenerative outcomes [12]. Such findings offer valuable insights for identifying novel and more effective therapeutic compounds in future research. Reportedly, loading matrine into exosomes synergistically enhances its anti‐inflammatory effects and promotes neovascularisation and tissue formation during wound healing [13]. These findings support the therapeutic potential of alkaloid substances in wound healing and provide a broader theoretical basis for the berberine (BBR) preconditioning strategy employed in the present study. BBR, a natural isoquinoline alkaloid derived from plants such as Berberis, Phellodendron and Canadian water hyacinth, exhibits a range of biological properties including notable antibacterial, anti‐inflammatory and antioxidant activities [14, 15]. Considering its favourable safety profile and potent broad‐spectrum antimicrobial efficacy, BBR represents a promising alternative to conventional single‐target antibiotics, particularly for the treatment of infected skin wounds [16]. Notably, studies have demonstrated that BMSCs preconditioned with BBR exhibit enhanced neuroprotective efficacy and a greater capacity to promote bone regeneration [17, 18]. Recent studies have demonstrated that BBR‐loaded hydrogels significantly accelerate wound closure by inhibiting bacterial growth, suppressing inflammatory cytokine release and enhancing collagen deposition and angiogenesis in both normal and diabetic wound models [19]. Furthermore, BBR has been shown to promote angiogenesis and tissue viability via the PI3K/Akt/eNOS signalling pathway in skin flap models [20], supporting its potential utility in regenerative skin therapies. Given the dual capacity of BBR to promote wound repair and augment the functional properties of BMSCs, this study aimed to investigate whether BBR‐preconditioned BMSCs (BMSCs‐BBR) exhibit superior therapeutic efficacy in burn wound healing. Materials and Methods Ethics Approval and Animal Treatment All experimental protocols received approval from the Ethics Committee of Zhejiang Baiyue Biotech Co. Ltd for Experimental Animals Welfare (Approval No. ZJBYLA‐IACUC‐20250422). A total of 24 Wistar albino rats (aged 8 weeks, body weight: 220–250 g) and 8 Sprague–Dawley rats (body weight: 60–80 g) were procured from the Experimental Animal Center of Hangzhou Medical College (China). Animals were housed under specific pathogen‐free (SPF) conditions, with controlled temperature (22°C ± 2°C), humidity (50% ± 10%) and a 12‐h light/dark cycle. Food and water were provided ad libitum in compliance with institutional guidelines for laboratory animal welfare. Isolation and Characterisation of BMSCs BMSCs were isolated from Sprague–Dawley rats under aseptic conditions. Following removal of inguinal adipose tissue, femora and tibiae were dissected and bone marrow plugs were extracted. The marrow tissue was suspended in phosphate‐buffered saline (PBS; abs9459, Absin) and mechanically dissociated by repeated aspiration through a 20‐gauge needle. The resulting suspension was layered onto an equal volume of Percoll solution (abs9102, Absin) and centrifuged at 900g for 20 min. The intermediate layer, enriched with BMSCs, was carefully aspirated using a Pasteur pipette, diluted with PBS and centrifuged again at 900g for 10 min. The cell pellet was resuspended in α‐MEM (abs9506, Absin) supplemented with sodium bicarbonate (abs42027417, Absin), penicillin–streptomycin (abs9244, Absin) and 10% foetal bovine serum (abs972, Absin), followed by incubation at 37°C in a 5% CO2 humidified atmosphere. Third‐passage cells were used in subsequent experiments. Flow cytometric analysis was performed to characterise BMSCs following incubation with anti‐CD34 (AB81289, Abcam), anti‐CD44 (AB316123, Abcam), anti‐CD73 (AB133582, Abcam), anti‐CD90 (AB133350, Abcam) and anti‐CD105 (AB156756, Abcam) antibodies. Preparation of Conditioned Medium (CM) Gel To determine the optimal preconditioning concentration, BMSCs were treated with various concentrations of BBR (1, 5, 10, 20 and 50 μM) for 24 h, and cell viability was assessed using the CCK‐8 assay (abs50003, Absin). BMSCs were cultured in medium with/without 10 μM BBR (200 275, Sigma‐Aldrich, USA) for 24 h. Total protein concentration in the CM was determined via Bradford assay (abs580304, Absin) prior to gel formulation. The gel was prepared based on previously reported methodologies [21] with the following composition: CM containing 0.05% total protein, 2% hydroxypropyl methylcellulose (HPMC), 0.3% Glydant Plus Liquid, 10% propylene glycol and demineralised water to 100%. Briefly, HPMC was slowly added to distilled water at 60°C under continuous magnetic stirring (600 rpm) until fully hydrated. The mixture was cooled to room temperature, after which propylene glycol, Glydant Plus Liquid and CM (or complete culture medium for placebo gel) were added sequentially with stirring. The final pH was adjusted to 6.8–7.2 using 1 M NaOH or HCl. Gels were freshly prepared each week and stored at 4°C. A placebo gel, used as a control, was formulated by replacing CM with complete culture medium. Burn Wound Modelling and Therapeutic Intervention Wistar albino rats were randomly assigned to four groups (n = 6 per group) based on Federer's formula for sample size estimation. Dorsal fur was shaved 24 h before burn induction. Under anaesthesia using isoflurane, a full‐thickness burn wound was created using a preheated 18‐mm diameter metal plate for 10 s without additional pressure. Group 1 (Model) received placebo gel (200 mg/cm2 wound area); Groups 2 and 3 (BMSCs and BMSCs‐BBR, respectively) were treated topically with CM gel containing 0.05% protein (200 mg/cm2 wound area); and Group 4 was administered with silver sulfadiazine cream (200 mg/cm2 wound area, 45 965, Thermo Scientific, USA). Treatments were applied once daily (9:00–10:00 AM) for 21 consecutive days. Before each application, the residual gel or cream from the previous treatment was gently removed using sterile saline‐moistened gauze. Following gel application, wounds were left uncovered to allow air exposure. Wound healing parameters, including mean diameter (average of vertical and horizontal measurements), hair regrowth and eschar formation, were monitored daily. On Day 21, all animals were euthanised under deep anaesthesia by intraperitoneal injection of sodium pentobarbital (150 mg/kg), and skin specimens were collected. Full‐thickness wound tissues including a 5 mm margin of surrounding normal skin were either preserved in 10% neutral buffered formalin or stored at −80°C. Histological and Immunofluorescence Evaluation Formalin‐fixed skin samples were embedded in paraffin and cut into 4‐μm‐thick sections using a Leica RM2016 microtome. Sections were stained with haematoxylin and eosin (G1003, Servicebio) and Masson's trichrome (G1006, Servicebio) according to established protocols. For immunofluorescence, tissue sections were incubated with CD31 primary antibodies (ab222783, Abcam, UK), and appropriate Alexa Fluor 647‐conjugated secondary antibodies (ab150075, Abcam). Imaging was performed using a CKX53 fluorescence microscope (Olympus, Japan). Western Blot Analysis Total protein was extracted from skin tissues using RIPA lysis buffer, and concentrations were determined with a BCA assay kit (PC0020, Solarbio, China). Proteins were denatured, separated on NuPAGE 4%–12% Bis‐Tris precast gels (NP0321BOX, Thermo Scientific) and transferred to PVDF membranes (YA1701, Solarbio). After blockage with 5% non‐fat milk, membranes were probed overnight at 4°C with antibodies targeting Collagen I (ab260043, Abcam), Collagen III (ab7778, Abcam), p‐PI3K (AF3241, Affinity, China), PI3K (4292, CST, USA), p‐AKT (ab38449, Abcam), AKT (ab8805, Abcam), eNOS (ab300071, Abcam) and GAPDH (ab8245, Abcam). Next, incubation with HRP‐conjugated anti‐rabbit (ab175781, Abcam) or anti‐mouse (ab205719, Abcam) secondary antibodies was conducted and signals were detected using BeyoECL Plus reagent (P0018S, Beyotime, China) on an iBright CL750 system (Thermo Scientific). Densitometric analysis was performed with normalisation to GAPDH. Statistical Analysis Quantitative data are expressed as mean ± standard deviation (SD). Intergroup comparisons were conducted using one‐way ANOVA followed by Tukey's post hoc test. All analyses were performed with GraphPad Prism version 8.0 and a p‐value < 0.05 was considered statistically significant. Results Phenotypic Characterisation of BMSCs Flow cytometric analysis was performed to definitively characterise the immunophenotype of the isolated BMSCs at passage 3. As illustrated in Figure 1A, the cells were uniformly negative for the haematopoietic marker CD34 (> 90% negative), which effectively excluded the presence of haematopoietic stem cells, progenitor cells and leukocytes within the culture. Conversely, the cells exhibited high positivity (> 80%) for the adhesion molecules CD44, CD73, CD90 and CD105. CD44 is a key adhesion molecule associated with MSC homing, migration and immunomodulatory functions, while CD73, CD90 and CD105 are established positive markers for mesenchymal stromal cells. This distinct marker profile, CD34−, CD44+, CD73+, CD90+ and CD105+, demonstrated the successful isolation and purification of a homogeneous population of BMSCs, which was a fundamental prerequisite for the reliability and interpretation of all subsequent experiments. Immunophenotypic characterization of rat bone marrow‐derived mesenchymal stem cells (BMSCs) at passage 3 by flow cytometry. (A) Representative flow cytometry histograms showing the expression of cell surface markers CD34 and CD44. (B) Cytotoxicity of berberine (BBR) on BMSCs assessed by CCK‐8 assay at various concentrations (1, 5, 10, 20, and 50 μM) for 24 hours. Data are presented as mean ± SD from three independent experiments (n = 3). Statistical significance was determined using one‐way ANOVA followed by Tukey's post hoc test. Cytotoxicity of Berberine on BMSCs Prior to preconditioning, we evaluated the cytotoxic effects of BBR on BMSCs to establish a safe and effective concentration range. CCK‐8 assay revealed that BBR at concentrations of 1, 5 and 10 μM did not significantly compromise cell viability relative to the untreated control (Figure 1B). In contrast, higher concentrations of 20 and 50 μM markedly reduced cell viability, respectively (Figure 1B, p < 0.01). These findings indicated that 10 μM represented the maximal non‐cytotoxic concentration capable of maintaining BMSC viability above 90%, and was therefore selected as the optimal preconditioning dose for subsequent CM preparation. BMSCs‐CM With BBR Enhanced Burn Wound Healing The therapeutic efficacy of the CM gels on full‐thickness burn wounds was evaluated over 21 days. Macroscopic observation of wound closure at Days 7, 14 and 21 revealed distinct healing rates among the groups (Figure 2A). Wounds treated with the CM derived from BBR‐preconditioned BMSCs (BMSCs‐BBR group) demonstrated the fastest wound closure, as evidenced by a significant reduction in wound diameter compared to the Model (placebo gel) and other treatment groups at multiple time points. The BMSCs‐CM group also exhibited accelerated wound healing, though to a lesser extent than the BMSCs‐BBR group, while the Silver Sulfadiazine group showed an intermediate effect between the two. BMSCs‐BBR enhanced burn wound healing and improved skin histology. (A) Macroscopic appearance of burn wounds over a 21‐day period in different treatment groups: Model (placebo gel), BMSCs‐CM (conditioned medium from untreated BMSCs), BMSCs‐BBR (conditioned medium from BBR‐preconditioned BMSCs), and silver sulfadiazine. Wound healing parameters, including mean diameter, hair regrowth, and eschar formation, were monitored daily. Images were captured on Days 7, 14 and 21 post‐injury (n = 6 per group). (B) Representative haematoxylin and eosin (H&E)‐stained sections of wound tissues harvested on Day 21. Formalin‐fixed, paraffin‐embedded tissue sections (4 μm) were stained with haematoxylin and eosin (H&E; G1003, Servicebio) according to standard protocols. Images were acquired using an Olympus CKX53 microscope. Scale bar = 200 μm (×200). n = 6 per group. (C) Representative Masson's trichrome‐stained sections of Day‐21 wound tissues. Collagen fibres were stained blue. Sections (4 μm) were stained with Masson's trichrome (G1006, Servicebio) according to established protocols. Images were acquired using an Olympus CKX53 microscope. Scale bar = 200 μm (×200). n = 6 per group. Treatment With BMSCs‐BBR CM Ameliorated Histopathological Alterations and Promoted Collagen Organisation Histological evaluation using H&E staining on Day 21 post‐injury revealed that wounds treated with BMSCs‐BBR CM exhibited substantially improved tissue architecture, characterised by a fully regenerated epidermis, well‐formed granulation tissue and minimal inflammatory cell infiltration (Figure 2B). Masson's trichrome staining further demonstrated that the BMSCs‐BBR group displayed thicker, more densely packed and regularly arranged collagen fibres, with a significant reduction in fibrosis (Figure 2C). These structural improvements indicated that BMSCs‐BBR CM not only accelerated wound closure but also enhanced the quality of skin regeneration. BMSCs‐BBR Potentiated Collagen Deposition and Angiogenesis in Healed Skin Western blot analysis showed that protein levels of both Collagen I and Collagen III were significantly elevated in the BMSCs‐BBR group compared to BMSCs groups (Figure 3A–C, p < 0.05), indicating enhanced extracellular matrix (ECM) synthesis. Furthermore, immunofluorescence staining for CD31 revealed a marked increase in the density of CD31+ microvessels in wounds treated with BMSCs‐BBR CM (Figure 3D), demonstrating a pronounced pro‐angiogenic effect. BMSCs‐BBR promoted extracellular matrix deposition and angiogenesis, and activated the PI3K/AKT/eNOS signalling pathway. (A) Representative Western blot bands showing the protein expression levels of Collagen I and Collagen III in wound tissues from each group on Day 21. (B, C) Densitometric quantification of Collagen I (B) and Collagen III (C) protein levels normalised to GAPDH (mean ± SD, n = 3). Representative images showed that BMSCs‐BBR treatment increased Collagen I and Collagen III protein expression. *p < 0.05, **p < 0.01 versus Model group; & p < 0.05, &&& p < 0.001 versus BMSCs group. (D) Representative immunofluorescence staining for the endothelial cell marker CD31 (red) in wound beds. Cell nuclei were counterstained with DAPI (blue). Representative images showed that BMSCs‐BBR treatment enhanced CD31‐positive microvessel density. Scale bar = 200 μm (×200). n = 6 per group. (E) Representative Western blot bands of key proteins in the PI3K/AKT/eNOS pathway: Phosphorylated PI3K (p‐PI3K), total PI3K, phosphorylated AKT (p‐AKT), total AKT, endothelial nitric oxide synthase (eNOS), and GAPDH as a loading control. (F–H) Densitometric analysis of p‐PI3K/PI3K ratio (F), p‐AKT/AKT ratio (G), and the expression level of eNOS (H) normalised to GAPDH (mean ± SD, n = 3). Representative images showed that BMSCs‐BBR treatment upregulated p‐PI3K/PI3K, p‐AKT/AKT ratios and eNOS expression *p < 0.05, **p < 0.01 versus Model group; & p < 0.05, && p < 0.01, &&& p < 0.001 versus BMSCs group. BMSCs‐BBR Activated the PI3K/AKT/eNOS Signalling Pathway in Wound Tissue To explore the molecular mechanism underlying the improved healing, we assessed the activity of the PI3K/AKT/eNOS pathway, which is critical for cell survival and vascularisation. Western blot results indicated that treatment with BMSCs‐BBR CM significantly enhanced the phosphorylation of PI3K and AKT, and upregulated total eNOS protein (Figure 3E–H, p < 0.001). These data suggested that the therapeutic benefits of BMSCs‐BBR were mediated, at least in part, through activation of the PI3K/AKT/eNOS signalling axis. Discussion The management of burn wounds remains a persistent clinical challenge, necessitating the development of novel therapeutic strategies that accelerate closure while improving the quality of healing and minimising fibrosis. Given that prior studies using standard conditioned medium (CM) alone achieved only modest wound healing, the present study employed BBR preconditioning to pharmacologically stimulate BMSCs and augment their paracrine capacity, thereby generating an enhanced secretome with superior therapeutic efficacy to that of unconditioned CM. Our findings demonstrate that BBR preconditioning not only accelerated wound closure but also improved healing quality through activation of the PI3K/AKT/eNOS pathway, a mechanistic link previously unidentified in burn wound therapy. This preconditioning strategy represents a distinct approach to optimising CM‐based therapy rather than simply replicating existing CM applications. In this study, we demonstrated that a topical gel formulated from the CM of BMSCs‐BBR profoundly enhanced the repair of full‐thickness burn wounds in a rat model. Our principal findings indicated that BMSCs‐BBR treatment proved superior to both standard BMSCs‐CM and conventional silver sulfadiazine therapy, eliciting a multifaceted healing response characterised by accelerated re‐epithelialisation, enhanced collagen deposition and maturation and robust angiogenesis. Mechanistically, we identified the activation of the PI3K/AKT/eNOS signalling axis as a pivotal molecular mechanism underpinning these therapeutic benefits. First, our study provided compelling evidence that BMSCs‐BBR CM promoted not only the speed; more importantly, the quality of wound healing. The macroscopic observation of significantly accelerated wound contraction in the BMSCs‐BBR group was corroborated by detailed histological analysis. Although wound closure constitutes a critical endpoint, functional recovery ultimately depends on the architectural integrity and biomechanical properties of the regenerated skin. The H&E staining revealed a well‐organised epidermal structure and robust granulation tissue in the BMSCs‐BBR‐treated wounds, starkly contrasting with the disorganised and hyperplastic epithelium in the Model group. This was further reinforced by Masson's trichrome staining, which corroborated that BMSCs‐BBR CM facilitated the deposition of a denser, more regularly arranged collagen matrix, approximating the basket‐weave pattern of native skin. This finding holds substantial clinical importance, as excessive and disorganised collagen is a hallmark of scarring and fibrosis [22, 23]. The concomitant upregulation of both Collagen I and Collagen III, as confirmed by Western blot, indicated an active and balanced remodelling of the ECM. A coordinated ratio of these collagens is essential during the proliferative phase of healing, as its dysregulation compromises tensile strength and predisposes to pathological scarring [24, 25]. Collectively, our data suggested that BMSCs‐BBR CM created a microenvironment conducive to regenerative over purely reparative healing. Second, we delved into the underlying mechanisms and established that the enhanced healing was intrinsically linked to amplified angiogenesis via the PI3K/AKT/eNOS pathway. Our results showed that BMSCs‐BBR CM significantly upregulated p‐PI3K, p‐AKT and eNOS protein levels in wound tissue, indicating activation of this signalling axis. This conditioned medium delivered bioactive factors secreted by BMSCs to the wound bed, where they activated PI3K/AKT/eNOS signalling in resident cells to enhance angiogenesis and collagen deposition, as evidenced by increased CD31+ microvessels and elevated Collagen I/III expression. Angiogenesis, the formation of new blood vessels from pre‐existing ones, is indispensable for successful wound healing as it delivers oxygen, nutrients and immune cells to the burgeoning wound bed [26, 27]. Our immunofluorescence data showed a marked increase in CD31+ microvessels in wounds treated with BMSCs‐BBR CM, directly correlating with the improved tissue regeneration. This pro‐angiogenic effect can be largely attributed to the activation of the PI3K/AKT/eNOS signalling cascade, a well‐conserved pathway regulating endothelial cell survival, proliferation, migration and nitric oxide (NO) production [28, 29]. Our Western blot results clearly proved a significant increase in the phosphorylation of PI3K and AKT, along with elevated expression of total eNOS protein in the BMSCs‐BBR group. Upon AKT‐mediated activation, eNOS produces NO, a potent vasodilator and a key signalling molecule that promotes endothelial cell function and vascular permeability [5]. This mechanistic cascade aligned with the established role of this pathway in angiogenesis and positioned it as a central effector for the therapeutic efficacy of BMSCs‐BBR CM. It was plausible that the CM from preconditioned cells was enriched with factors that activated this signalling cascade in resident endothelial cells, thus initiating the angiogenic process [20]. Third, we critically evaluated the comparative efficacy of silver sulfadiazine, which served as a clinically relevant positive control. Macroscopic observations indicated that the healing rate of the silver sulfadiazine group was intermediate between the BMSCs and BMSCs‐BBR groups. Interestingly, despite its intermediate healing rate, the silver sulfadiazine treatment group exhibited significantly increased deposition of collagen I and collagen III and higher CD31 microvessel density compared to both BMSCs and BMSCs‐BBR groups. This unexpected finding may have multiple plausible explanations: the antimicrobial properties of silver sulfadiazine can effectively inhibit pathogen colonisation in wounds, indirectly preserving the viability of endogenous fibroblasts and endothelial cells by maintaining a sterile environment [30], thereby promoting native collagen synthesis and angiogenesis [31]. Meanwhile, although the burn model was established under aseptic conditions, the open wound remained susceptible to environmental contamination during the 21‐day healing period, which places acellular conditioned medium therapies (lacking intrinsic antibacterial capacity) at a distinct disadvantage. These findings demonstrate that infection control remains an indispensable cornerstone of burn wound management, and that even advanced regenerative biologics may underperform if microbial burden is not concurrently addressed. However, the superiority of silver sulfadiazine in collagen and vascular parameters did not translate into the most rapid wound closure or the most organised histological architecture. Nevertheless, BMSCs‐BBR conditioned medium achieved faster macroscopic healing and superior epidermal regeneration. Therefore, an optimal burn therapeutic strategy may ultimately require a combinatorial approach integrating the antimicrobial protection of silver sulfadiazine with the regenerative paracrine activity of BMSCs‐BBR conditioned medium. The present study was not designed to test such combination therapies, a limitation that represents an important direction for future investigation. A pivotal question addressed by our research is the source of the enhanced potency, which we attribute to the ‘preconditioning’ strategy with BBR. The consistent superiority of BMSCs‐BBR CM over standard BMSCs‐CM across all parameters underscored the indispensable role of this pretreatment. While our findings on the efficacy of MSC‐derived CM [32, 33, 34] and the involvement of the PI3K/AKT pathway [35, 36] in wound healing are consistent with existing literature, our study uniquely identified that BBR preconditioning synergistically enhanced the CM's pro‐healing activities. We postulated that BBR, a natural isoquinoline alkaloid with documented anti‐inflammatory, anti‐apoptotic and metabolism‐modulating properties [14, 15], acted as a potent stimulus that ‘primes’ the BMSCs [37, 38]. This reprogramming likely induces the cells to secrete a more robust and potentially unique cocktail of trophic factors, cytokines and exosomes, an ‘enhanced’ secretome potentially rich in pro‐angiogenic factors (e.g., VEGF, FGF‐2), ECM‐modulating proteins (e.g., TIMPs, fibronectin) and anti‐inflammatory mediators [39, 40], which collectively contribute to the observed outcomes. More importantly, we provided a comprehensive mechanistic link by systematically demonstrating the concurrent activation of PI3K, AKT and eNOS specifically in this context, a finding not previously reported for burn wound therapy. This strategy not only elegantly circumvented challenges associated with whole‐cell transplantation but also positioned BMSCs‐BBR CM as a superior, next‐generation acellular therapeutic approach. Notwithstanding the promising results, we acknowledged the limitations of our study. Firstly, while we have demonstrated a strong correlation between the activation of the PI3K/AKT/eNOS pathway and the improved healing phenotype, a definitive causal relationship should be verified by rescue experiments using specific pathway inhibitors (e.g., LY294002 for PI3K or L‐NAME for eNOS). Secondly, the precise composition of the ‘enhanced’ secretome in BMSCs‐BBR CM remains to be fully elucidated. A proteomic analysis of the CM would be invaluable for identifying the key bioactive factors upregulated by BBR preconditioning, which could lead to the development of an optimised, defined molecular cocktail. In conclusion, our findings establish that the topical application of a gel containing CM from BBR‐preconditioned BMSCs represents a highly effective strategy for treating burn wounds. This therapy promotes rapid and high‐quality tissue regeneration by enhancing collagen synthesis and orchestrating a robust angiogenic response, predominantly through the activation of the PI3K/AKT/eNOS signalling pathway. The preconditioning approach unveils a promising avenue for maximising the therapeutic potential of MSC‐derived paracrine factors. Future research focusing on the detailed characterisation of the secretome and the validation of the mechanism through functional inhibition will be essential for translating this potent acellular therapy into clinical practice. Funding This research was supported by the Zhejiang Provincial Medical Science and Technology Plan Project (grant numbers 2024KY1836). Conflicts of Interest The authors declare no conflicts of interest.